Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Torben Noerup Nielsen who wrote (549)	1/24/2000 12:43:00 AM
From: enervestor	Respond to of 52153

CRXA is high on my buy on dips list. I have been impressed with the way their management picked up Anergen and Ribi for practically nothing. I have never understood why more of these basically bankrupt companies weren't picked up for their technology when they were almost being given away. CRXA has the benefit of three companies research now instead of just one for a fraction of the cost it took do the research. I am just skeptical they can hold today's prices if the biotech sector runs out of steam.

To: Torben Noerup Nielsen who wrote (549)	1/24/2000 9:04:00 AM
From: scaram(o)uche	Read Replies (2) \| Respond to of 52153

First of all, I don't know who this Richard guy is that you keep referring to. <g> CRXA.... mixed feelings, and haven't looked for almost two years, since Miljenko went to their ASCO presentation and reported back..... best efforts among the cancer vaccines that don't integrate dendritic cells, IMO. Promised a diagnostic for Her-1/Neu that was never delivered?? Please, again, realize that this is way old, and I'm just responding because you seem to like my comments, no matter how lame. I do not like the RIBI adjuvant, and I've used it head-to-head in my own experiments with appropriate controls. Not particularly impressed by that acquisition, but..... it didn't look like their own proprietary adjuvant (Leif, or something like that??) was moving much, and (2) Ribi does have a significant number of collaborative studies..... while the adjuvant isn't great, there isn't much out there (saponin derivatives?) that is better among the non-toxics. I do like the Anergen acquisition, but..... only because of a gut feeling that there must be value if Dr. Maureen Howard went there. We could all use an outline of their current projects. I'll find and bookmark the thread. You might also see if Miljenko has commented lately, as he was following them. I've followed the CEO's here and at Dendreon since they were founders of Immunex. IMO, they had little to do with the eventual success there. Doesn't mean that they weren't effective, and I forget the details. Be careful of assuming that company founders are good managers, just because the company was successful subsequently. However, looks like CRXA was moving and shaking at the correct time, showing foresight at the correct time. Long way of saying that I don't know much. I'll bookmark the thread and watch for an outline of their current projects. Rick